|PUBLICATIONS (Ranked by impact factor of the journal)|
Ultra Low-Dose IL-2 for Graft-versus-Host Disease Prophylaxis after Allogeneic HSCT Mediates Expansion of Regulatory T Cells without Diminishing Anti-Viral and Anti-Leukemic Activity|
Scientists prospectively evaluated the effects of ultra low-dose IL-2 injections on CD4+CD25+FoxP3+ regulatory T-cells (Tregs) recovery in pediatric patients after allogeneic hematopoietic stem cell transplantation (alloSCT) and compared this recovery with Treg reconstitution post alloSCT in patients without IL-2. [Clin Cancer Res]
CTLA4 Blockade Broadens the Peripheral T Cell Receptor Repertoire
Investigators evaluated the immunomodulatory effects of CTLA-4 blockade with tremelimumab in peripheral blood mononuclear cells (PBMC). Scientists used next generation sequencing to study the complementarity determining region 3 from the rearranged T cell receptor variable beta in PBMC of 21 patients, at baseline and 30-60 days after receiving tremelimumab. [Clin Cancer Res]
Nerve Growth Factor Downregulates Inflammatory Response in Human Monocytes through TrkA
The authors showed that nerve growth factor (NGF) is part of a regulatory loop in monocytes: inflammatory stimuli, while activating a proinflammatory response through TLRs, upregulate the expression of the NGF receptor TrkA. In turn, NGF, by binding to TrkA, interferes with TLR responses. In TLR-activated monocytes, NGF reduces inflammatory cytokine production while inducing the release of anti-inflammatory mediators. [J Immunol]
Neutrophil Gelatinase-Associated Lipocalin Increases HLA-G+/FoxP3+ T-Regulatory Cell Population in an In Vitro Model of PBMC
Researchers aimed to understand whether neutrophil gelatinase-associated lipocalin modulates the T-cell response through regulation of the human leukocyte antigen G complex, which is a mediator of tolerance. [PLoS One]
The Role of Regulatory T Cell (Treg) Subsets in Gestational Diabetes Mellitus
Investigators hypothesized that gestational diabetes mellitus (GDM) may be caused by an inappropriate adaption of the maternal immune system to pregnancy. They examined the role of Treg differentiation for the development of GDM during pregnancy. [Clin Exp Immunol]
Potential Non-T Cells Source of Interleukin-4 in Food Allergy
A previous study showed that allergen-induced IL-4 expression in CD25+ mononuclear cells was increased in allergic patients. However, researchers did not find the expected increase in GATA-3 expression, suggesting that allergen-induced IL-4 might not be of T-cell origin. Researchers sought to determine whether other cell types were responsible for the increased IL-4 expression in the CD25+ cell population. [Pediatr Allergy Immunol]
Evidence for Non-Neutralizing Autoantibodies against IL-10 Signaling Components in Patients with Inflammatory Bowel Disease
The authors investigated the existence of inhibitory autoantibodies against interleukin-10 (IL-10) and IL-10 receptor (IL-10R) in inflammatory bowel disease patients capable of down-modulating IL-10 signaling thereby mimicking IL-10 or IL-10R deficiency. [BMC Immunol]
|Subscribe to our sister publications: Immunology of Infectious Disease News
and Immune Regulation News!|
Immune Design Announces Treatment of First Patient in Phase I Clinical Trial of ID-G305 Cancer Immunotherapy Agent |
Immune Design announced treatment of the first patient in a Phase I clinical trial of ID-G305, a cancer immunotherapy investigational agent from the company’s GLAASTM platform. [Immune Design]
New Drugs Bring Optimism to Graft-versus-Host Disease Treatment
Outcomes are gradually improving for patients who suffer from graft-versus-host disease, one of the most serious complications of stem cell transplantation, and researchers are optimistic that further advances may be on the way. [Dana-Farber Cancer Institute]
ImmunoCellular Therapeutics Receives Orphan Drug Status for ICT-107 in Glioblastoma in the European Union
ImmunoCellular Therapeutics, Ltd. announced that the European Medicines Agency has granted orphan drug designation for ICT-107 for the treatment of patients with glioblastoma. ICT-107 is an intradermally administered autologous vaccine consisting of the patient’s dendritic cells pulsed with six synthetic tumor-associated antigens: AIM-2, MAGE-1, TRP-2, gp100, HER-2, IL-13Rα2. [ImmunoCellular Therapeutics, Ltd.]
THYMISTEM Researches Stem Cell Therapies for Damaged Immune Systems
Studies show that transplanting thymus cells into patients can be an effective way to repair and restore the immune system; however the lack of a source for these specialized cells represents a major barrier. In the previous studies, scientists used cells from newborn babies that had been removed as a normal part of heart surgery. Cells from adult donors are shown not to have the same effect. The THYMISTEM team seeks to overcome this by finding new methods of producing thymus stem cells in the lab as an alternative source of cells for therapy. [European Commission]
From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
Have we missed an important article or publication in Human Immunology News?
Click here to submit!
Comments or Suggestions? Submit your feedback here.